With an extensive career in the pharmaceutical industry spanning over 30 years, Kaela Porter brings a wealth of experience and expertise to her role as Director of Clinical Pharmacology, particularly in the realm of preclinical and clinical DMPK (Drug Metabolism and Pharmacokinetics). She has been a leading figure in the research and development of therapeutics for ALS and various other CNS conditions.

At AcuraStem, Porter continues to innovate and push the boundaries of CNS drug development, aiming to improve the lives of patients worldwide. Porter’s responsibilities encompass meticulous study design, data interpretation, and the planning and execution of follow-up studies. She plays a significant role in target engagement and biomarker validation and is integral in planning and drafting phase 1 trial protocols that incorporate exploratory biomarkers.

Prior to joining AcuraStem, Porter served in various senior roles, contributing to the development and approval of key pharmaceutical products. As the Principal and Founder of Porter Pharmaceutical Services, she guided her firm towards the discovery and development of innovative therapies. Prior to that, she played a crucial role in the approval of Avonex®, a treatment for multiple sclerosis, while working as a Scientist I at Biogen, Inc. Porter has been involved in successful BLA and NDA filings for drugs such as Avonex®, Opana ER, and XPOVIO™. These medicines have revolutionized the treatment of multiple sclerosis, pain management, and certain types of cancer, respectively.

Her academic training as a pharmacokineticist has greatly shaped her professional path and continues to drive her research at AcuraStem. She remains an active member of several professional societies, including the American Association of Pharmaceutical Scientists, New England Drug Metabolism Group, and the European Society of Clinical Microbiology and Infectious Disease.